Results 21 to 30 of about 780 (156)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19

Infection and Drug Resistance, 2023
Cheng-Yi Hu,1 Wen-Shuai Cui,1 Yi Lei,1 Yu-Wen Tang,1 Yan-Yan Zhang,1 Qi-Min Su,1 Fang Peng,2 Yun-Fei Zeng,1 Jia-Lin Song,1 Cheng-Na Luo,1 Yan Zhou,1 Xin-Yan Li,1 Zhu-Xiang Zhao1 1Department of Infectious Diseases, Guangzhou First People’s Hospital ...
Hu CY, Cui WS, Lei Y, Tang YW, Zhang YY, Su QM, Peng F, Zeng YF, Song JL, Luo CN, Zhou Y, Li XY, Zhao ZX   +12 more
doaj   +4 more sources

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases [PDF]

Virology Journal
Background Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown.
Guanyue Su, Feng Gao, Mengzhao Yang, Ling Wang, Lili Liang, Silin Li, Guangming Li, Na Han, Guotao Li, Guowu Qian, Shixi Zhang, Hong Luo, Donghua Zhang, Hongxia Liang, Zhigang Ren   +14 more
doaj   +2 more sources

Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China. [PDF]

Front Med (Lausanne)
ObjectiveThe aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden ...
Yuan W, Liu Y, Zhan H, Wei F, Zhang Q, Gao H, Yan H, Huang T, Li Y, Dai E.   +9 more
europepmc   +3 more sources

Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study [PDF]

Heliyon
Background: Azvudine was approved for the treatment of coronavirus disease 2019 (COVID-19) in China and has been widely used since the outbreak in December 2022. However, real-world research on the adherence of Azvudine is lacking.
Hui Yang, Ying Zhang, Zhaojian Wang, Man Xu, Yushu Wang, Yi Zhang, Xin Feng, Zhuoling An   +7 more
doaj   +2 more sources

Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study [PDF]

Acta Pharmaceutica Sinica B
Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1 ...
Yuanchao Zhu, Fei Zhao, Yubing Zhu, Xingang Li, Deshi Dong, Bolin Zhu, Jianchun Li, Xin Hu, Zinan Zhao, Wenfeng Xu, Yang Jv, Dandan Wang, Yingming Zheng, Yiwen Dong, Lu Li, Shilei Yang, Zhiyuan Teng, Ling Lu, Jingwei Zhu, Linzhe Du, Yunxin Liu, Lechuan Jia, Qiujv Zhang, Hui Ma, Ana Zhao, Hongliu Jiang, Xin Xu, Jinli Wang, Xuping Qian, Wei Zhang, Tingting Zheng, Chunxia Yang, Xuguang Chen, Kun Liu, Huanhuan Jiang, Dongxiang Qu, Jia Song, Hua Cheng, Wenfang Sun, Hanqiu Zhan, Xiao Li, Yafeng Wang, Aixia Wang, Li Liu, Lihua Yang, Nan Zhang, Shumin Chen, Jingjing Ma, Wei Liu, Xiaoxiang Du, Meiqin Zheng, Liyan Wan, Guangqing Du, Hangmei Liu, Pengfei Jin   +54 more
doaj   +2 more sources

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +2 more sources

A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes [PDF]

Frontiers in Endocrinology
IntroductionDuring the Omicron infection wave, diabetic patients are susceptible to COVID-19, which is linked to a poor prognosis. However, research on the real-world effectiveness and safety of Azvudine, a common medication for COVID-19, is insufficient
Yongjian Zhou, Zecheng Yang, Shixi Zhang, Donghua Zhang, Hong Luo, Di Zhu, Guangming Li, Mengzhao Yang, Xiaobo Hu, Guowu Qian, Guotao Li, Ling Wang, Silin Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +2 more sources

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +3 more sources

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

View
Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
doaj   +2 more sources

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis

Heliyon, 2023
Introduction: Azivudine has undergone a few randomized controlled trials (RCTs) as of late. This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety.
Zhaoyan Chen, Fangyuan Tian
doaj   +3 more sources